Mariner, LLC Ionis Pharmaceuticals Inc Transaction History

Mariner, LLC

$51.1 Billion
Q2 2024

A detailed history of Mariner, LLC transactions in Ionis Pharmaceuticals Inc stock. As of the latest transaction made, Mariner, LLC holds 21,854 shares of IONS stock, worth $882,027. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,854

Previous 20,784 5.15%

Holding current value

$882,027

Previous $900,000 15.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$36.45 - $47.7 $39,001 - $51,039	1,070 Added 5.15%	21,854 $1.04 Million
Q1 2024 May 15, 2024	BUY	$42.03 - $53.55 $4,707 - $5,997	112 Added 0.54%	20,784 $900,000
Q4 2023 Feb 14, 2024	BUY	$43.39 - $51.63 $120,797 - $143,737	2,784 Added 15.56%	20,672 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$38.5 - $47.13 $19,789 - $24,224	514 Added 2.96%	17,888 $811,000
Q2 2023 Aug 11, 2023	BUY	$34.73 - $43.33 $376,924 - $470,260	10,853 Added 166.43%	17,374 $712,000
Q1 2023 May 12, 2023	SELL	$33.58 - $41.2 $370,085 - $454,065	-11,021 Reduced 62.83%	6,521 $233,000
Q4 2022 Feb 14, 2023	BUY	$37.12 - $46.52 $386,085 - $483,854	10,401 Added 145.65%	17,542 $663,000
Q3 2022 Nov 10, 2022	BUY	$36.54 - $48.66 $260,932 - $347,481	7,141 New	7,141 $316,000
Q3 2019 Nov 13, 2019	SELL	$59.06 - $72.15 $194,720 - $237,878	-3,297 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$62.09 - $86.14 $3,973 - $5,512	64 Added 1.98%	3,297 $212,000
Q1 2019 May 15, 2019	SELL	$52.92 - $81.17 $131,082 - $201,058	-2,477 Reduced 43.38%	3,233 $262,000
Q4 2018 Feb 13, 2019	BUY	$43.37 - $59.54 $247,642 - $339,973	5,710 New	5,710 $309,000

Others Institutions Holding IONS

# of Institutions

390

Shares Held

125M

Call Options Held

2.25M

Put Options Held

510K

View Full List

About IONIS PHARMACEUTICALS INC

Ticker IONS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,940,992
Market Cap $5.73B
Description
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for famil...

More about IONS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mariner, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mariner, LLC with notifications on news.

Account